Please use this identifier to cite or link to this item:
|Title:||Sphingolipids and hepatic steatosis||Authors:||Bikman, B.T.
|Issue Date:||2011||Abstract:||The development of a fatty liver predisposes individuals to an array of health problems including diabetes, cardiovascular disease and certain forms of cancer. Inhibition or genetic ablation of genes controlling sphingolipid synthesis in rodents resolves hepatic steatosis and in many cases wards off the health complications associated with excessive hepatic triglyceride accumulation. Examples include the pharmacological inhibition of serine palmitoyltransferase or glucosylceramide synthase or the genetic depletion of acid sphingomyelinase, which dramatically reduce hepatic triglyceride levels in mice susceptible to the development of a fatty liver. The magnitude of the effects on triglyceride depletion in these models is impressive, but the relevance to humans and the mechanism of action is unclear. Herein we probe into the connections between sphingolipids and triglyceride synthesis in an attempt to identify causal relationships and opportunities for therapeutic intervention. © 2011 Landes Bioscience and Springer Science+Business Media, LLC.||Source Title:||Advances in Experimental Medicine and Biology||URI:||http://scholarbank.nus.edu.sg/handle/10635/126544||ISBN:||9781461406495||ISSN:||00652598||DOI:||10.1007/978-1-4614-0650-1_6|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 1, 2021
checked on Jul 31, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.